(Q43580864)

English

Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group

scientific article published in December 1996

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 November 2017

Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group (English)

1 reference

Europe PubMed Central

24 November 2017

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Feig SA

1

1 reference

Europe PubMed Central

24 November 2017

Ames MM

2

1 reference

Europe PubMed Central

24 November 2017

Sather HN

3

1 reference

Europe PubMed Central

24 November 2017

Steinherz L

4

1 reference

Europe PubMed Central

24 November 2017

Reid JM

5

1 reference

Europe PubMed Central

24 November 2017

Trigg M

6

1 reference

Europe PubMed Central

24 November 2017

Pendergrass TW

7

1 reference

Europe PubMed Central

24 November 2017

Warkentin P

8

1 reference

Europe PubMed Central

24 November 2017

Gerber M

9

1 reference

Europe PubMed Central

24 November 2017

Leonard M

10

1 reference

Europe PubMed Central

24 November 2017

Bleyer WA

11

1 reference

Europe PubMed Central

24 November 2017

Harris RE

12

1 reference

Europe PubMed Central

24 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 December 1996

1 reference

Europe PubMed Central

24 November 2017

Pediatric Blood Cancer

1 reference

Europe PubMed Central

24 November 2017

27

1 reference

Europe PubMed Central

24 November 2017

505-514

1 reference

Europe PubMed Central

24 November 2017

6

1 reference

Europe PubMed Central

24 November 2017

Bone marrow transplantation in children

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Which treatment for childhood acute lymphoblastic leukaemia in second remission?

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report fro

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Estimation of the proportional hazard in two-treatment-group clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Analysis of Survival Data under the Proportional Hazards Model

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Improved treatment results in the management of single and multiple relapses of acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Bone-marrow transplantation has a limited role in prolonging second marrow remission in childhood lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Effect of various substitutions in positions 1, 2, 3, and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycin

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199612%2927%3A6%3C505%3A%3AAID-MPO1%3E3.0.CO%3B2-P

21 January 2018

Identifiers

10.1002/(SICI)1096-911X(199612)27:6<505::AID-MPO1>3.0.CO;2-P

1 reference

Europe PubMed Central

24 November 2017

1 reference

Europe PubMed Central

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43580864&oldid=2101634235"